

CASE STUDY 1:

Cost Advantages and Continuous Local Management

- The first three steps from a registered process, previously run in Switzerland on 1,600 L scale, were successfully transferred to operations in India within a timeframe of five months.
- The intermediate of an API which goes generic in a few years required us to provide larger quantities of intermediates at lower costs.
- The process is now being performed on a scale up to 4,000 L with the intermediate being sent to Switzerland for further conversion to the final API.
- This approach offers the maximum flexibility in handling the cost and quantity demands of the product in development and commercialisation life cycles. The customer benefits from cost advantage and continuous local project management.

CASE STUDY 2:

Customer Dedicated Facilities

- A large, multinational pharmaceutical company required significant cost of goods reduction to deliver a market leading drug product.
- Dishman optimised the process and built a dedicated facility for the API production.
- Dishman further reduced costs by developing its own more cost-effective routes for the three key starting materials. An overall cost reduction of more than 50% was achieved.
- Routine commercial manufacture is now ongoing at the Bavla site, offering the customer significant cost advantages and a simplified and secure supply chain.

CASE STUDY 3:

Commercialisation from a Laboratory Process within 12 months

- A European Speciality Pharmaceutical company approached Dishman for the contract manufacture of a late life cycle API. The Client had a non-infringing laboratory scale process for the API which needed optimisation and scale up to commercial production.
- The process was transferred & then optimised at an R&D level. This was followed by pilot scale validation batches and then 10mT commercial production within 9 months of initiating technology transfer.
- During the commercial production, alternative, more cost effective supply solutions were found for key starting materials & these were incorporated into production post validation.
- An agreed regulatory programme was completed and Dishman provided the Client with a full technical dossier to enable regulatory filings.
- As a consequence of the success of this program, the Client has transferred a further 3 projects into the Dishman group.

Dishman Carbogen Amcis Group Contacts:

api.asia@dishmangroup.com

api.europe@dishmangroup.com

api.usa@dishmangroup.com

This list is not to be construed as a representation of non-infringement or as an offer to sell in those countries where such would constitute an infringement of third parties' patent rights.

© July 2018 Dishman Carbogen Amcis Group

**ENERGISE YOUR
SCIENCE FOR LIFE**

www.dishmangroup.com